Sidus Space Launches Fortis™ VPX: A Ruggedized, AI-Powered 3U OpenVPX Module Supporting Complex Missions from Sea to Space
Fortis™ VPX provides the scalable digital backbone needed to accelerate mission development timelines, reduce integration complexity, and support software-defined operations.
Share
Fortis™ VPX provides the scalable digital backbone needed to accelerate mission development timelines, reduce integration complexity, and support software-defined operations. Leveraging an open architecture and industry-standard 3U VPX form factor, Fortis™ is built for rapid integration into a range of applications across maritime, land, space, and airborne domains.
'Fortis™ VPX is a force multiplier for AI-driven mission systems,' said Carol Craig, CEO of Sidus Space. 'Its modularity, computing power, and SOSA™ aligned compatibility enables customers to quickly adapt to evolving mission requirements while reducing total lifecycle costs.'
Strategic Alignment & Market Relevance
With integrated AI/ML processing, secure navigation, and robust C&DH capabilities, Fortis™ VPX is positioned at the intersection of defense modernization, commercial space infrastructure, and autonomous systems development. The systems' modularity and dual-use applicability support a broad spectrum of use cases across satellite constellations, tactical ground systems, unmanned aerial vehicles (UAV), and intelligence, surveillance, and reconnaissance (ISR) platforms.
Alignment with the SOSA™ Technical Standard and Sidus' proprietary IP supports recurring revenue opportunities through both system sales and service-based contracts across defense, aerospace, maritime, and commercial end uses.
Why Fortis™ VPX Is Like No Other
Proven AI in Space Since 2023: Sidus Space leads the edge-computing revolution in orbit, with operational AI deployment in 2023, positioning Sidus as one of the earliest entrants with heritage in space-qualified AI/Edge platforms
Capturing VPX Market Momentum: Fortis™ VPX targets the rapidly growing market and expanding requirements for autonomous, edge-deployed intelligence in defense and aerospace sectors
Strategic Focus on Edge AI Capabilities: Engineered to enable autonomous, low-latency AI processing at the edge, Fortis™ VPX meets the surging demand for near real-time intelligence across multiple domains
Smart, Software-Defined Payload Architecture: Fortis™ combines VPX single board computers (SBC) with FeatherEdge™ AI to enable dynamic, software-defined payloads capable of adapting to changing mission parameters across domains
Multi-Domain, Modular Platform: Designed for seamless deployment across all operational domains:
Air: Tactical UAV systems
Sea: Underwater autonomous vehicles
Land: ISR ground systems and mobile C2 nodes
Space: Radiation-hardened VPX AI payloads
Spaceflight Heritage: Our FeatherEdge™ AI system, now integrated with Fortis™, has achieved Technology Readiness with LizzieSat™-3, demonstrating full mission qualification in orbit
Scalable, Agile Manufacturing: Sidus combines vertical integration with rapid manufacturing processes to deliver Fortis™ VPX at scale
'The recent launch of China's first AI-focused satellite, part of a planned 2,800-satellite constellation, signals a global acceleration in edge AI computing,' said Val Ojdanic, Chief Technology Officer at Sidus Space. 'Fortis™ VPX is built to meet this demand with the scalability, ruggedization, and AI readiness required to power next-generation infrastructure across domains.'
About Sidus Space
Sidus Space (NASDAQ: SIDU) is a space mission enabler providing flexible, cost-effective solutions, including satellite manufacturing and technology integration, AI-driven space-based data solutions, mission planning and management operations, AI/ML products and services, and space and defense hardware manufacturing. With its mission of Space Access Reimagined®, Sidus Space is committed to rapid innovation, adaptable and cost-effective solutions, and the optimization of space system and data collection performance. With demonstrated space heritage, including manufacturing and operating its own satellite and sensor system, LizzieSat®, Sidus Space serves government, defense, intelligence, and commercial companies around the globe. Strategically headquartered on Florida's Space Coast, Sidus Space operates a 35,000-square-foot space manufacturing, assembly, integration, and testing facility and provides easy access to nearby launch facilities. For more information, visit: www.sidusspace.com.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Sidus Space's Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Sidus Space, Inc. specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Cathie Wood Pours Millions Into Archer Aviation and Pony AI Push
Aug 13 - Cathie Wood's ARK funds made headlines again on Tuesday with a trio of bold moves in aviation and autonomy. ARK bought roughly $3.15 million of Archer Aviation (NYSE:ACHR) stock and added about $13.37 million of Pony AI (NASDAQ:PONY), signaling renewed appetite for eVTOL and robotaxi plays. At the same time ARK sold 282,737 shares of Kratos Defense (NASDAQ:KTOS), a disposal that totaled about $18.49 million as Wood rebalances the portfolio. Warning! GuruFocus has detected 2 Warning Sign with ACHR. The trades show ARK doubling down on next-gen mobility while trimming some defense exposure after KTOS's recent rally. Other smaller purchases included stakes in Caris Life Sciences (NASDAQ:CAI), Illumina (NASDAQ:ILMN) and Exact Sciences (NASDAQ:EXAS), alongside buys in mega-caps such as Amazon (NASDAQ:AMZN) and Deere (DE). ARK's move could push investor interest back into high-growth, speculative mobility names, but it also underscores the fund's active, high-conviction approach to thematic investing. This article first appeared on GuruFocus. Sign in to access your portfolio
Business Wire
7 minutes ago
- Business Wire
Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype for MTB on Rapid-Deploy SeekIt™ Platform
SALT LAKE CITY--(BUSINESS WIRE)--Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt™ platform. In internal analytical testing, the MTB SeekIt test delivered accurate results in under 60 minutes. Importantly, this innovation addresses a key limitation that has historically hindered effective TB diagnostics: breaking apart MTB's waxy, lipid-rich cell wall to gain access to detectable genetic material. In internal testing, SeekIt's proprietary chemical lysis step achieved this in just 15 minutes without heat, mechanical disruption, or complex lab tools and skilled operators. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. Share Seek Lab's MTB test demonstrates the speed, adaptability, and field-readiness of the modular SeekIt platform. All SeekIt's components—lysis chemistry, extraction, amplification, and detection—are proprietary to Seek Labs, exclusively discovered and developed in-house, and have been internally validated for performance and integration across multiple applications. The Global TB Testing Gap TB kills more than 1.25 million people each year, with nearly one in three cases going undiagnosed. In high-burden, resource-limited settings, centralized molecular tests face major hurdles: Pathogen complexity: MTB's waxy, lipid-rich cell wall has proven intractable to portable lysis methods for decades. Infrastructure dependence: Gold-standard molecular tests require expensive, power-intensive instruments, refrigeration, and highly skilled (or trained) operators. Sample limitations: Sputum collection is challenging for many patients and can deter testing. 'TB diagnostics have long been limited by gaps in both infrastructure and innovation that have often meant severe consequences for patient care and public health,' said Jared Bauer, CEO of Seek Labs. 'Our rapid, point-of-care SeekIt MTB test is designed to enable molecular-level detection in settings where access to equipment and electricity may be limited.' From Sample to Result: A Simplified Workflow At the core of the MTB SeekIt test is a proprietary, single-step chemical lysis buffer, involving a specially-formulated solution that disrupts MTB cells to release their genomic DNA. This breakthrough innovation takes just 15 minutes at room temperature, while competing methods (high-heat incubation or mechanical bead-beating) require longer times plus expensive equipment, specialized technicians, and complex infrastructure. More importantly, the integrated SeekIt test means the lysate itself flows seamlessly into SeekIt's downstream test components: Seek Extraction™ — A proprietary membrane-based binding system, developed and validated by Seek Labs, that rapidly captures MTB DNA without lab instruments. In validation testing, the MTB DNA yield for Seek Extraction was consistently more than 70% when compared to leading spin-column kits. Seek Amplification™ — A proprietary process that exponentially copies DNA at a constant temperature, detecting as few as 10 MTB genomic copies in 30 minutes without thermal cycling (internally validated), the conventional lab-based method. Molecular Lateral Flow Assay (mLFA) — A test strip that delivers clear, visual results in minutes indicating the presence of amplified DNA in a manner that can be optionally paired with the SeekIt mobile app for digital analysis and connectivity. Speed as a Strategy Conventional development of a molecular test for MTB can take a year or more. Seek Labs achieved a functional investigational prototype in one quarter by leveraging its suite of in-house, pre-validated diagnostic technologies, focusing new innovation efforts on the MTB-specific lysis step. This rapid-deployment approach illustrates how SeekIt can be rapidly developed for numerous high-priority diseases in record time. 'This was more than a fast project; it's proof of our platform's flexibility,' said Kim Wirthlin, Chief Strategy Officer. 'By focusing our innovation on the MTB-specific lysis step for compatibility with our downstream isothermal amplification, we solved one of TB diagnostics' toughest technical challenges and produced a functional investigational prototype in a single quarter.' From Conference to Collaboration Seek Labs will debut the MTB SeekIt prototype at the 2025 Next Generation Dx Conference (August 18–20, 2025, Washington, D.C.), including: Podium Presentation — Enabling Point of Care Diagnostics Track, Tuesday, August 19 at 10:00 AM ET. Scientific Poster — Detailing the proprietary lysis chemistry, rapid development process, and validation data. Seek Labs is actively seeking partners across global health (ministries of health, TB-focused NGOs, and diagnostics distributors in high-burden regions such as sub-Saharan Africa and Southeast Asia) to advance the MTB SeekIt test through clinical validation, regulatory approval, and deployment. 'Innovation means nothing if it doesn't reach people,' said Bauer. 'We want to work with those who share our vision to advance development of accurate, accessible TB testing solutions wherever they're needed most.' About Seek Labs At Seek Labs, we don't wait for change—we build it. We're pursuing the breakthroughs the world can't wait for by developing programmable 'seek-and-destroy' therapeutics and point-of-care molecular diagnostics that close the gap between outbreak and intervention. At the core of this mission is a layered architecture: BioSeeker™ serves as the Intelligence Layer, continuously mapping conserved viral vulnerabilities in real time; these insights activate our Deployment Layers (PTAP™ for programmable therapeutics and SeekIt™ for molecular diagnostics), forming a full-stack development engine designed to accelerate response, innovation, and impact across global health. Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah's collaborative life sciences ecosystem. Together with our partners, we're building faster, smarter solutions for the world's most urgent health challenges. Forward-Looking Statements and Regulatory Disclaimer This press release contains forward-looking statements, including statements regarding development timelines, clinical validation, regulatory pathways, and potential collaborations. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties—including scientific, regulatory, manufacturing, clinical, and commercial risks—that could cause actual results to differ materially. The MTB SeekIt assay is an investigational device. Limited by Federal law to investigational use.
Yahoo
11 minutes ago
- Yahoo
US stocks rally to records on hopes for cuts to interest rates
NEW YORK (AP) — The U.S. stock market rallied to records on Tuesday after data suggested inflation across the country was a touch better last month than economists expected. The S&P 500 rose 1.1% to top its all-time high set two weeks ago. The Dow Jones Industrial Average climbed 483 points, or 1.1%, and the Nasdaq composite jumped 1.4% to set its own record. Stocks got a lift from hopes that the better-than-expected inflation report will give the Federal Reserve leeway to cut interest rates at its next meeting in September. Lower rates would give a boost to investment prices and to the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment. President Donald Trump has angrily been calling for cuts to help the economy, often insulting the Fed's chair personally while doing so. But the Fed has been hesitant because of the possibility that Trump's tariffs could make inflation much worse. Lowering rates would give inflation more fuel, potentially adding oxygen to a growing fire. That's why Fed officials have said they wanted to see more data come in about inflation before moving. Tuesday's report said U.S. consumers paid prices for groceries, gasoline and other costs of living that were overall 2.7% higher in July than a year earlier. That's the same inflation rate as June's, and it was below the 2.8% that economists expected. The report pushed traders on Wall Street to increase bets that the Fed will cut interest rates for the first time this year in September. They're betting on a 94% chance of that, up from nearly 86% a day earlier, according to data from CME Group. The Fed will receive one more report on inflation, as well as one more on the U.S. job market, before its next meeting, which ends Sept. 17. The most recent jobs report was a stunner, coming in much weaker than economists expected. Some economists warn that more twists and turns in upcoming data could make the Fed's upcoming decisions not so easy. Its twin goals are to get inflation to 2% while keeping the job market healthy. Helping one with interest rates, though, often means hurting the other. Even Tuesday's better-than-expected inflation report had some discouraging undertones. An underlying measure of inflation, which economists say does a better job of predicting where inflation may be heading, hit its highest point since early this year, noted Gary Schlossberg, market strategist at Wells Fargo Investment Institute. That helped cause some up-and-down swings for Treasury yields in the bond market. 'Eventually, tariffs can show up in varying degrees in consumer prices, but these one-off price increases don't happen all at once,' said Brian Jacobsen, chief economist at Annex Wealth Management. 'That will confound the Fed and economic commentators for months to come.' Other central banks around the world have been lowering interest rates, and Australia's on Tuesday cut for the third time this year. On Wall Street, Intel's stock rose 5.6% after Trump said its CEO has an 'amazing story,' less than a week after he had demanded Lip-Bu Tan's resignation. Circle Internet Group, the company behind the popular USDC cryptocurrency that tracks the U.S. dollar, climbed 1.3% despite reporting a larger loss for the latest quarter than analysts expected. It said its total revenue and reserve income grew 53% in its first quarter as a publicly traded company, which topped forecasts. On the losing side of Wall Street was Celanese, which sank 13.1% even though the chemical company delivered a better profit than expected. It said that customers in most of its markets continue to be challenged, and CEO Scott Richardson said that 'the demand environment does not seem to be improving.' Cardinal Health dropped 7.2% despite likewise reporting a stronger profit for the latest quarter than analysts expected. Its revenue fell short of forecasts, and analysts said the market's expectations were particularly high for the company after its stock had already soared 33.3% for the year coming into the day. Critics say the broad U.S. stock market is looking expensive after its surge from a bottom in April. That's putting pressure on companies to deliver continued growth in profit. All told, the S&P 500 rose 72.31 points to 6,445.76. The Dow Jones Industrial Average climbed 483.52 to 44,458.61, and the Nasdaq composite jumped 296.50 to 21,681.90. In stock markets abroad, indexes edged up in China after Trump signed an executive order late Monday that delayed hefty tariffs on the world's second-largest economy by 90 days. The move was widely expected, and the hope is that it will clear the way for a possible deal to avert a dangerous trade war between the United States and China. Japan's Nikkei 225 jumped 2.1%, and South Korea's Kospi fell 0.5% for two of the world's bigger moves. In the bond market, the yield on the 10-year Treasury rose to 4.28% from 4.27% late Monday. The yield on the two-year Treasury, which more closely tracks expectations for the Fed, fell to 3.73% from 3.76%. ___ AP Business Writers Yuri Kageyama and Matt Ott contributed.
